The biological operability of XXXX .

@entity1 @entity5 @entity957 @entity1149 @entity3 @entity420
@entity5 represents a broad spectrum of anatomical and histological subsets of @entity1 with differing biological characteristics and prognostic expectations. Our experience with 161 consecutive @entity1 undergoing complete resection for @entity5 at the M. D. Anderson Hospital and @entity5 Institute from 1965 through 1980 includes 69 @entity1 with T3 N0 or N1 disease and 92 @entity1 with an N2 classification. The cumulative 5-year survival overall was 30%: 35.6% for the T3 N0 or N1 group and 26% for the N2 @entity1 . Seventy-three @entity1 had @entity957 and 76, @entity420 . Small numbers of @entity1 had other miscellaneous classifications (N = 12). In the T3 N0 or N1 subset, 43% of the @entity1 with @entity957 (N = 37) and 23% of those with @entity420 (N = 25) survived 5 years. In the N2 subset, 39% of the @entity1 with @entity957 (N = 36) and 14% of the group with @entity420 (N = 52) achieved long-term survival. Failure of treatment was clinically documented in 61 @entity1 . The first observed recurrence or @entity3 was at a distant site in the majority of these @entity1 . Operative intervention for @entity1 with Stage III M0 @entity1149 is effective and reflects the impact and limitations of resection on disease progression. Adjuvant irradiation was not shown to improve the outcome over the results of operation alone. Effective systemic therapy will be required to produce substantial changes in end results.
